

Dear Friends & Colleagues

The Locust Walk Partners team is proud to share with you today's news of our client, InterMune's, divestiture of Actimmune® (interferon gamma-1b) to Vidara Therapeutics. Having now completed **7 transactions over the past 21 months** and assisting leading biotechnology and pharmaceutical companies with their strategic planning efforts, we look forward to helping you achieve your transaction and strategic objectives.

With best regards,

The Locust Walk Partners team

Commercial Stage Asset Divestiture

Situation Assessment

- InterMune (NASDAQ: ITMN) is a public, commercial stage biopharmaceutical on the research, development and commercialization of innovative therapies in pulmonology and fibrotic diseases.
- Actimmune® (interferon gamma-1b) is approved for two ultra orphan indications: chronic granulomatous disease and osteopetrosis. Actimmune® was considered non-strategic and deemed a divestiture candidate.
- Selected Locust Walk Partners as its exclusive business and corporate development advisor to divest Actimmune[®].

Key Activities

- Prepared high impact teaser and management presentation
- Conducted an outreach to >80 leading global and regional companies, both publicly traded and privately
 held, that are active in the development and commercialization of ultra-orphan and /or high value
 biologic agents.
- Led multiple parties through a confidential diligence process leading to competing term sheets and contracts.
- Led negotiations on financial terms and actively participated in face-to-face negotiations of the term sheet and definitive agreement.

Successful Outcome

- Competitive process resulted in an acquisition of Actimmune® for \$55M plus two years of royalties, nearly 3x the last 12 month net revenues (as of March 31, 2012).
- Upfront payment and near-term economics exceeded the client's expectations due to Locust Walk Partners' process and negotiations.
- The Vidara management team has been successful in the sale of their previous company, Alaven, to Meda for \$350M.